8-KThe WireStrategic
Results of Operations
Filed May 6, 2026 · 1mo ago · Accession 0001193125-26-208918
Plain English
Revolution Medicines, Inc. announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress, including positive topline results from the Phase 3 RASolute 302 trial of daraxonrasib.
Filing details
- Company
- Revolution Medicines, Inc.
- Ticker
- RVMD
- CIK
- 1628171
- Form type
- 8-K
- Filing date
- May 6, 2026
- Report date
- May 6, 2026
- Document
- rvmd-20260506.htm
- Size
- 340 KB